High Expression of High Mobility Group Box 1 (hmgb1) Predicts Poor Prognosis for Hepatocellular Carcinoma After Curative Hepatectomy

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2012 Jul 4

PMID 22747650

Citations 29

Authors

Furong Liu

Yaojun Zhang

Zhenwei Peng

Hengjun Gao

Li Xu

Minshan Chen

Affiliations

Soon will be listed here.

Abstract

Background: High mobility group box 1(HMGB1) overexpression has been reported in a variety of human cancers. However, the role of HMGB1 in hepatocellular carcinoma (HCC) remains unclear. The aim of present study was to analyze HMGB1 protein expression in tumor, para-tumor and normal tissue and to assess its prognostic significance for HCC after curative hepatectomy.

Methods: The levels of HMGB1 mRNA and protein in tumor, para-tumor and normal tissue were evaluated in 11 HCC cases by Reverse Transcription-polymerase chain reaction (RT-PCR) and Western blot. Additionally, HMGB1 protein expression in 161 HCC was analyzed by immunohistochemistry and correlated with clinicopathological characteristics and survivals. Student's t-test, spearman's rank correlation, Kaplan-Meier plots and Cox proportional hazards regression model were used to analyze the data.

Results: By RT-PCR and Western blot, the levels of HMGB1 mRNA and protein were significantly higher in HCC, compared to that in para-tumor (p < 0.001) and normal tissue (p < 0.001). Immunohistochemical staining revealed that high expression of HMGB1 was detected in 42.9% (69/161) HCC cases. High expression of HMGB1 was significantly associated with incomplete encapsulation (p = 0.035) and advanced TNM stage (p = 0.036). Multivariate analysis showed that high expression of HMGB1 was an independent prognostic factor for both overall (p = 0.009, HR = 1.834, 95%CI: 1.167-2.881) and disease-free survival (p = 0.018, HR = 1.622, 95%CI: 1.088-2.419), along with tumor size. Subgroup analysis revealed that high expression of HMGB1 predicted poorer overall survival only for tumor >5 cm (p = 0.031), but not for tumor ≤5 cm (p = 0.101).

Conclusions: HMGB1 protein might contribute to the malignant progression of HCC, high expression of HMGB1 predicts poor prognosis for patients with HCC after curative hepatectomy, especially for patients with tumor >5 cm.

Citing Articles

Assessment of combined serum sST2 and AFP levels in the diagnosis of hepatocellular carcinoma.

Tang X, Wang D, Ding T, Lin R, He M, Wang R PeerJ. 2024; 12:e18142.

PMID: 39677962 PMC: 11639131. DOI: 10.7717/peerj.18142.

Molecular determinants of immunogenic cell death elicited by radiation therapy.

Galassi C, Klapp V, Yamazaki T, Galluzzi L Immunol Rev. 2023; 321(1):20-32.

PMID: 37679959 PMC: 11075037. DOI: 10.1111/imr.13271.

HMGB1-mediated elevation of KLF7 facilitates hepatocellular carcinoma progression and metastasis through upregulating TLR4 and PTK2.

Feng W, Chen J, Huang W, Wang G, Chen X, Duan L Theranostics. 2023; 13(12):4042-4058.

PMID: 37554278 PMC: 10405848. DOI: 10.7150/thno.84388.

A murine cellular model of necroinflammation displays RAGE-dependent cytokine induction that connects to hepatoma cell injury.

Bachmann M, Lamprecht L, Gonther S, Pfeilschifter J, Muhl H J Cell Mol Med. 2020; 24(18):10356-10366.

PMID: 32697038 PMC: 7521286. DOI: 10.1111/jcmm.15649.

microRNA-548b suppresses aggressive phenotypes of hepatocellular carcinoma by directly targeting high-mobility group box 1 mRNA.

Yun Z, Meng F, Jiang P, Yue M, Li S Cancer Manag Res. 2019; 11:5821-5834.

PMID: 31417317 PMC: 6601050. DOI: 10.2147/CMAR.S198615.

References

Stros M, Ozaki T, Bacikova A, Kageyama H, Nakagawara A . HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter. J Biol Chem. 2001; 277(9):7157-64. DOI: 10.1074/jbc.M110233200. View

Tafani M, Schito L, Pellegrini L, Villanova L, Marfe G, Anwar T . Hypoxia-increased RAGE and P2X7R expression regulates tumor cell invasion through phosphorylation of Erk1/2 and Akt and nuclear translocation of NF-{kappa}B. Carcinogenesis. 2011; 32(8):1167-75. DOI: 10.1093/carcin/bgr101. View

Jiang W, Wang Z, Li X, Fan X, Duan Y . High-mobility group box 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Pathol Oncol Res. 2011; 18(2):293-8. DOI: 10.1007/s12253-011-9442-3. View

Liang H, Zhong Y, Zhou S, Peng L . Knockdown of RAGE expression inhibits colorectal cancer cell invasion and suppresses angiogenesis in vitro and in vivo. Cancer Lett. 2011; 313(1):91-8. DOI: 10.1016/j.canlet.2011.08.028. View

Bruix J, Boix L, Sala M, Llovet J . Focus on hepatocellular carcinoma. Cancer Cell. 2004; 5(3):215-9. DOI: 10.1016/s1535-6108(04)00058-3. View

Bao G, Qiao Q, Zhao H, He X . Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas. World J Surg Oncol. 2010; 8:52. PMC: 2909949. DOI: 10.1186/1477-7819-8-52. View

Cheng B, Jia C, Liu C, Lu X, Zhong N, Zhang Z . Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis. 2008; 40(6):446-52. DOI: 10.1016/j.dld.2007.11.024. View

Llovet J . Updated treatment approach to hepatocellular carcinoma. J Gastroenterol. 2005; 40(3):225-35. DOI: 10.1007/s00535-005-1566-3. View

Qin Y, Dai S, Tang G, Zhang J, Ren D, Wang Z . HMGB1 enhances the proinflammatory activity of lipopolysaccharide by promoting the phosphorylation of MAPK p38 through receptor for advanced glycation end products. J Immunol. 2009; 183(10):6244-50. DOI: 10.4049/jimmunol.0900390. View

10.

Luan Z, Zhang H, Yang P, Ma X, Zhang C, Guo R . HMGB1 activates nuclear factor-κB signaling by RAGE and increases the production of TNF-α in human umbilical vein endothelial cells. Immunobiology. 2010; 215(12):956-62. DOI: 10.1016/j.imbio.2009.11.001. View

11.

Bustin M, Hopkins R, Isenberg I . Immunological relatedness of high mobility group chromosomal proteins from calf thymus. J Biol Chem. 1978; 253(5):1694-9. View

12.

Tang D, Kang R, Zeh 3rd H, Lotze M . High-mobility group box 1 and cancer. Biochim Biophys Acta. 2010; 1799(1-2):131-40. PMC: 2818552. DOI: 10.1016/j.bbagrm.2009.11.014. View

13.

Yang J, Chen L, Yang J, Ding J, Rong H, Dong W . High mobility group box-1 induces migration of vascular smooth muscle cells via TLR4-dependent PI3K/Akt pathway activation. Mol Biol Rep. 2011; 39(3):3361-7. DOI: 10.1007/s11033-011-1106-6. View

14.

Semino C, Angelini G, Poggi A, Rubartelli A . NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood. 2005; 106(2):609-16. DOI: 10.1182/blood-2004-10-3906. View

15.

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

16.

Lotze M, Tracey K . High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005; 5(4):331-42. DOI: 10.1038/nri1594. View

17.

Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G, Zitvogel L . Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res. 2008; 68(11):4026-30. DOI: 10.1158/0008-5472.CAN-08-0427. View

18.

Penzo M, Molteni R, Suda T, Samaniego S, Raucci A, Habiel D . Inhibitor of NF-kappa B kinases alpha and beta are both essential for high mobility group box 1-mediated chemotaxis [corrected]. J Immunol. 2010; 184(8):4497-509. PMC: 2915896. DOI: 10.4049/jimmunol.0903131. View

19.

Yang H, Rivera Z, Jube S, Nasu M, Bertino P, Goparaju C . Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci U S A. 2010; 107(28):12611-6. PMC: 2906549. DOI: 10.1073/pnas.1006542107. View

20.

Zayed H, Izsvak Z, Khare D, Heinemann U, Ivics Z . The DNA-bending protein HMGB1 is a cellular cofactor of Sleeping Beauty transposition. Nucleic Acids Res. 2003; 31(9):2313-22. PMC: 154227. DOI: 10.1093/nar/gkg341. View